Search for a clinical trial
Other search option(s)
21 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PRECISION 2: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination (HR) Genes, a Belgian Precision phase II basket study
Universitair Ziekenhuis Brussel
Oncologisch centrum
GERMANY
Bayern
WÜRZBURG
SPENCER: A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma - DE
Universitätsklinikum Würzburg
GERMANY
Bayern
WÜRZBURG
ADIUVO: Efficacy of adjuvant mitotane treatment in prolonging disease-free survival in patients with adrenocortical cacinoma at low-intermediate risk of recurrence (Phase III) - DE
Zentrum Innere Medizin (ZIM)
Medizinische Klinik und Poliklinik I - Endokrinologie und Diabetologie
ITALY
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
SPENCER: A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma - IT
Institution: Information not provided - IT
ITALY
LOMBARDIA
BRESCIA
ABACUS - Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
ASST Spedali Civili di Brescia
U.O.Oncologia
ITALY
PIEMONTE
TORINO
ADIUVO - Efficacy of adjuvant mitotane treatment in prolonging disease-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence (Phase III) - FR
University of Turin
Dipartimento di Scienze Cliniche e Biologiche
NETHERLANDS
Noord-Brabant
EINDHOVEN
ADIUVO - Efficacy Of Adjuvant Mitotane Treatment In Prolonging Recurrence-free Survival In Patients With Adrenocortical Carcinoma At Low-Intermediate Risk Of Recurrence (Phase III) - NL
Máxima Medisch Centrum, locatie Eindhoven
Afdeling Interne Geneeskunde
SPAIN
Cataluña
BARCELONA
SPENCER: A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
UNITED KINGDOM
West Midlands
BIRMINGHAM
ADIUVO - Efficacy of adjuvant mitotane in prolonging recurrence-free survival in patients with adrenocortical carcinoma at low-intermediate risk of recurrence (phase III) - UK
University of Birmingham
CEDAM - Centre for Endocrinology, Diabetes and Metabolism
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label Extension Study of the Safety of Relacorilant in the Treatment of the Signs and Symptoms of Cushing Syndrome (Phase II-III) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRADIENT: Glucocorticoid Receptor Antagonism in the Treatment of Hypercortisolism in Patients with Cortisol-Secreting Adrenal Adenomas or Hyperplasia: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
NETHERLANDS
Noord-Holland
AMSTERDAM
The Drug Rediscovery Protocol (DRUP trial): A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile (Phase II)
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Maag-Darm-Leveroncologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat (Phase 2) - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - AT
Institution: Information not provided - AT
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
STEP: Sorafenib Long Term Extension Program - BE
Cliniques universitaires Saint-Luc - UCLouvain
Pneumologie_Oncologie thoracique
BELGIUM
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease - BE
Universitair Ziekenhuis Brussel
Endocrinologie
ITALY
LAZIO
ROMA
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE GIANICOLO
U.O. di Oncoematologia
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
GRACE: Glucocorticoid Receptor Antagonism in the Treatment of Cushing Syndrome: A Phase 3, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study of the Efficacy and Safety of Relacorilant - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Osilodrostat - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome - ES
Institution: Information not provided - ES
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES